Table 1.

Patient characteristics

0.6 mg/kg (n = 6)0.9 mg/kg (n = 9)1.2 mg/kg (n = 14)Overall (n = 29)
Median age (years)64.5, n (%)56.0, n (%)60.5, n (%)59.0, n (%)
Gender
 Male5 (83.3)7 (77.8)11 (78.6)23 (79.3)
 Female1 (16.7)2 (22.2)3 (21.4)6 (20.7)
ECOG
 03 (50.0)6 (66.7)7 (50.0)16 (55.2)
 13 (50.0)3 (33.3)7 (50.0)13 (44.8)
Prior nephrectomy
 Yes6 (100.0)8 (88.9)14 (100.0)28 (96.6)
 No01 (11.1)01 (3.4)
Number of disease sites
 1002 (14.3)2 (6.9)
 ≥26 (100.0)9 (100.0)12 (85.7)27 (93.1)
Number of prior therapies
 12 (33.3)2 (22.2)7 (50.0)11 (37.9)
 ≥24 (66.7)7 (77.8)7 (50.0)18 (62.1)
Prior systemic therapies
 Sunitinib4 (66.7)6 (66.7)7 (50.0)17 (58.6)
 Pazopanib1 (16.7)5 (55.6)8 (57.1)14 (48.3)
 mTOR inhibitors3 (50.0)5 (55.6)5 (35.7)13 (44.8)
 Nivolumab1 (16.7)1 (11.1)1 (7.1)3 (10.3)
 Sorafenib1 (16.7)01 (7.1)2 (6.9)
 Bevacizumab1 (16.7)1 (11.1)02 (6.9)
 Interleukin-21 (16.7)01 (7.1)2 (6.9)
 Ipilimumab01 (11.1)01 (3.4)
  • Abbreviation: ECOG, Eastern Cooperative Oncology Group.